- Correction: The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. Kahn, Henry S // BMC Cardiovascular Disorders;2006, Vol. 6, p5
A correction to the article "The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison" that was published in the January 27, 2006 issue is presented.
- Corrigendum: Saposin C is required for lipid presentation by human CD1b. Winau, Florian; Schwierzeck, Vera; Hurwitz, Robert; Remmel, Natascha; Sieling, Peter A; Modlin, Robert L; Porcelli, Steven A; Brinkmann, Volker; Sugita, Masahiko; Sandhoff, Konrad; Kaufmann, Stefan H E; Schaible, Ulrich E // Nature Immunology;Mar2004, Vol. 5 Issue 3, p344
Presents a corrected reprint of an article on the role of saposin C in lipid presentation by human CD1b previously published in the periodical "Nature Immunology".
- Erratum: “Dynamics of vesicle formation from lipid droplet: Mechanism and controllability” [J. Chem. Phys. 130, 094905 (2009)]. Zilu Wang; Xuehao He // Journal of Chemical Physics;1/14/2010, Vol. 132 Issue 2, p029901
A correction to the article "Dynamics of Vesicle Formation from Lipid Droplet: Mechanism and Controllability" in the January 12, 2009 issue is presented.
- Erratum. // LC-GC Europe;Apr2008, Vol. 21 Issue 4, p188
A correction to the article "An Evaluation of the Determination of the Lipophilicity of Apocynin and Diapocynin Using HPLC," that was published in the February 2008 issue is presented.
- Re: “Amount and Intensity of Physical Activity, Physical Fitness, and Serum Lipids in Men”. // American Journal of Epidemiology;1996, Vol. 144 Issue 3, p317
The Journal is notified by Drs. Jaume Marrugat and Roberto Elosua of two errors in table 5 of their recently published paper (1).The authors point out that in the published version of table 5, the Î² coefficients for VO2max and for the constant are misaligned. In the published table, the row...
- Correction: Abundant Genetic Overlap between Blood Lipids and Immune-Mediated Diseases Indicates Shared Molecular Genetic Mechanisms. Andreassen, Ole A.; Desikan, Rahul S.; Wang, Yunpeng; Thompson, Wesley K.; Schork, Andrew J.; Zuber, Verena; Doncheva, Nadezhda T.; Ellinghaus, Eva; Albrecht, Mario; Mattingsdal, Morten; Franke, Andre; Lie, Benedicte A.; Mills, Ian G.; Aukrust, Pål; McEvoy, Linda K.; Djurovic, Srdjan; Karlsen, Tom H.; Dale, Anders M. // PLoS ONE;May2015, Vol. 10 Issue 5, p1
No abstract available.
- Correction: Analysis of Lipid Experiments (ALEX): A Software Framework for Analysis of High-Resolution Shotgun Lipidomics Data. // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1
No abstract available.
- Lipids. Goldemberg, Robert L. // DCI;Sep96, Vol. 159 Issue 3, p70
Reports on the introduction of lipids and related compounds by various cosmetics companies during the 1996 Supplier's Day show. Includes hydrogenated polyisobutene from Lipo Chemicals; Mona Industries' gamma linolenic acid derived from starflower oil; Biomimetic lipid matrix from Brooks Industries.
- Potent stuff. Portyansky, Elena // Drug Topics;7/21/97, Vol. 141 Issue 14, p26
Reports that approval has been given for a third-generation HMG-CoA reductase inhibitor, BAYCOL (cerivastatin sodium). Response of Frederick S. Mayer, who is involved in cholesterol counseling programs; Information on the lipid buster made by Bayer Pharmaceutical Division, in West Haven,...